Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.46 USD
Change Today +0.0604 / 0.94%
Volume 12.6K
PULM On Other Exchanges
As of 5:20 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

pulmatrix inc (PULM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/14 - $15.88
52 Week Low
07/27/15 - $5.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PULMATRIX INC (PULM)

Related News

No related news articles were found.

pulmatrix inc (PULM) Related Businessweek News

No Related Businessweek News Found

pulmatrix inc (PULM) Details

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its iSPERSE technology. The company’s proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease and other treatments. Pulmatrix, Inc. is based in Lexington, Massachusetts.

13 Employees
Last Reported Date: 05/4/15
Founded in 2003

pulmatrix inc (PULM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $314.0K
Chief Scientific Officer
Total Annual Compensation: $249.9K
Compensation as of Fiscal Year 2014.

pulmatrix inc (PULM) Key Developments

Pulmatrix Appoints William Duke Jr. as Chief Financial Officer

Pulmatrix has appointed William Duke Jr. as chief financial officer. Duke previously worked as CFO for Valeritas Inc. Prior to Valeritas, Duke also worked at Genzyme and Haemonetics Corporation.

Pulmatrix, Inc. Appoints William Duke as Chief Financial Officer

Pulmatrix, Inc. announced the appointment of William Duke, Jr., as chief financial officer. Mr. Duke previously served as chief financial officer of Valeritas, Inc. He has more than 20 years of experience in finance leadership roles, with the majority coming at life sciences companies including Valeritas, Genzyme and Haemonetics. Prior to his role as chief financial officer of Valeritas, Mr. Duke held various leadership roles in finance and accounting for public and private companies. Previously, he served as a Senior Director of Finance at Genzyme Corporation and as a Director of Finance/Accounting at Haemonetics Corporation.

Pulmatrix, Inc.(NasdaqCM:PULM) added to NASDAQ Composite Index

Pulmatrix, Inc. has been added to Nasdaq Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PULM:US $6.46 USD +0.0604

PULM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PULM.
View Industry Companies

Industry Analysis


Industry Average

Valuation PULM Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PULMATRIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at